On Wednesday, Wolfe Research raised its rating on shares of Tenet Healthcare (NYSE:THC) from Peer Perform to Outperform, setting a price target of $122.00. The firm cited the potential upside from the increase in Michigan supplemental Medicaid payments expected in 2024, along with Tenet's ongoing deleveraging efforts.
The analyst from Wolfe Research noted that the new price target is based on an 8.25x enterprise value to estimated EBITDA-NCI (Earnings Before Interest, Taxes, Depreciation, and Amortization - Net of Company Interest). This valuation does not yet factor in any potential financial benefits from the Michigan Medicaid payment increase.
The upgrade comes as Tenet Healthcare continues to focus on reducing its debt levels, a strategy that Wolfe Research has previously discussed. The analyst's outlook suggests confidence in the company's financial trajectory and its ability to capitalize on the favorable changes in Medicaid payments in Michigan.
The new price target of $122.00 represents a significant increase and reflects the positive expectations that Wolfe Research has for Tenet Healthcare's financial performance. The upgrade to Outperform indicates that the firm believes Tenet's stock will perform better than the broader market in the near future.
Investors and market watchers will likely monitor Tenet Healthcare's progress as it works towards achieving the outlined financial improvements and takes advantage of the evolving healthcare payment landscape in Michigan.
InvestingPro Insights
Following Wolfe Research's optimistic outlook on Tenet Healthcare, insights from InvestingPro further enrich the narrative for investors considering THC. With a perfect Piotroski Score of 9, Tenet Healthcare demonstrates strong financial health, which could be a reassuring signal for potential investors. This score indicates that the company is performing well across a variety of accounting-based measures.
Moreover, Tenet Healthcare's management has been actively buying back shares, which often reflects leadership's confidence in the company's future and can be a positive sign for share valuation. The company's low P/E ratio of 13.04 relative to its near-term earnings growth suggests that the stock may be undervalued, providing an attractive entry point for investors. Additionally, the stock's strong free cash flow yield is an indicator of financial flexibility and the potential for future investments or shareholder returns.
For those seeking more detailed analysis and additional insights, there are 17 more InvestingPro Tips available, which can be accessed through the tailored InvestingPro platform for Tenet Healthcare. As investors consider the Wolfe Research upgrade and the company's strategic financial maneuvers, these additional metrics and tips can provide a more comprehensive understanding of THC's investment potential. To gain full access to these insights, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.